Attovia Therapeutics Stock (NASDAQ:ATTO)
Previous Close
$19.55
52W Range
$16.15 - $24.32
50D Avg
$20.41
200D Avg
$20.41
Market Cap
$908.79M
Avg Vol (3M)
$589.64K
Beta
-
Div Yield
-
ATTO Company Profile
A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases.